A detailed history of Strategic Blueprint, LLC transactions in Amgen Inc stock. As of the latest transaction made, Strategic Blueprint, LLC holds 5,809 shares of AMGN stock, worth $1.81 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
5,809
Previous 5,600 3.73%
Holding current value
$1.81 Million
Previous $1.61 Million 2.42%
% of portfolio
0.12%
Previous 0.14%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

BUY
$268.87 - $324.56 $56,193 - $67,833
209 Added 3.73%
5,809 $1.65 Million
Q4 2023

Jan 25, 2024

BUY
$255.7 - $288.46 $14,063 - $15,865
55 Added 0.99%
5,600 $1.61 Million
Q3 2023

Oct 18, 2023

BUY
$218.65 - $271.46 $11,369 - $14,115
52 Added 0.95%
5,545 $1.49 Million
Q2 2023

Oct 18, 2023

SELL
$214.27 - $253.37 $99,849 - $118,070
-466 Reduced 7.82%
5,493 $1.22 Million
Q1 2023

Apr 28, 2023

BUY
$225.79 - $275.2 $85,348 - $104,025
378 Added 6.77%
5,959 $1.44 Million
Q4 2022

Jan 26, 2023

SELL
$229.03 - $291.01 $1,374 - $1,746
-6 Reduced 0.11%
5,581 $0
Q3 2022

Nov 08, 2022

BUY
$224.46 - $253.15 $11,671 - $13,163
52 Added 0.94%
5,587 $1.26 Million
Q2 2022

Aug 12, 2022

BUY
$230.71 - $256.74 $1.28 Million - $1.42 Million
5,535 New
5,535 $1.35 Million
Q3 2021

Nov 12, 2021

SELL
$212.27 - $248.7 $37,571 - $44,019
-177 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$233.58 - $259.14 $41,343 - $45,867
177 New
177 $43,000
Q1 2021

May 10, 2021

SELL
$221.91 - $258.6 $2.09 Million - $2.43 Million
-9,412 Closed
0 $0
Q4 2020

Jan 26, 2021

BUY
$216.38 - $257.67 $2.04 Million - $2.43 Million
9,412 New
9,412 $2.16 Million
Q4 2019

Jan 10, 2020

SELL
$189.21 - $243.2 $44,275 - $56,908
-234 Closed
0 $0
Q3 2019

Oct 16, 2019

BUY
$174.11 - $208.62 $40,741 - $48,817
234 New
234 $45,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $166B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Strategic Blueprint, LLC Portfolio

Follow Strategic Blueprint, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategic Blueprint, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Strategic Blueprint, LLC with notifications on news.